Show less
Quarterly Outlook video: The new mantra
Dembik Christopher
Yesterday at 12:06 GMT
Quarterly Outlook video: Don the helmets
Steen Jakobsen
Thursday at 13:58 GMT
How has the Opec deal hit FX?
John J Hardy
Thursday at 10:25 GMT
What is a combination order ticket? - webinar
Georgio Stoev
Thursday at 10:17 GMT
Why I'm long FTSE 100: O'Hare
Steve O'Hare - First 4 Trading
Thursday at 7:13 GMT
Gold’s safe-haven status on hold
Ole Hansen
Wednesday at 8:59 GMT
Why I’m trading EuroStoxx (Dec 16): Lucas
Steve Lucas
Wednesday at 7:05 GMT
What do gasoline prices say about the oil trade?
Futures Institute
Tuesday at 8:21 GMT
Why I'm shorting EURUSD: Coleman
Ian Coleman - First 4 Trading
Tuesday at 7:13 GMT
Could USD weakness see risk-on shift?
Kay Van-Petersen
Monday at 15:19 GMT
Technical Analysis - webinar
Kim Cramer Larsson
Monday at 14:16 GMT
Trading tips week 39 - technical analysis
James Kim@Saxo
Monday at 10:22 GMT
The regime of dollar weakness
Kay Van-Petersen
Monday at 8:40 GMT
Video / 18 June 2014 at 9:07 GMT

Should we all be investing in Irish healthcare?

Peter Garnry
What is it with Ireland's healthcare companies? In the past week alone, we've heard that the US giant Medtronic wants to buy Dublin based Covidien for USD 43 billion. On Tuesday it was reported that Citi has been hired by the Irish pharma company, Shire, as it's expecting takeover bids. It raises the question, should we all be investing in Irish pharmaceutical and biotech companies? 
Saxo Bank's Head of Equity Strategy, Peter Garnry, says that's certainly what the market seems to be telling you right now. He says this is a trend that could last for years. Many multinationals, notably in the States, view Ireland as a highly favourable tax base as they pay considerably less corporation tax and it's much easier to repatriate cash flows if they were to be based in the Emerald Isle. 
On top of that, he says a number of Irish healthcare companies are looking good in their own right. Shire has been one of his top equity picks for weeks as it has good profit margins, valuations, and growth prospects. He also suggests that the Pfizer deal with the UK's AstraZeneca may also be revived soon. 


The Saxo Bank Group entities each provide execution-only service and access to permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on or as a result of the use of the Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. When trading through your contracting Saxo Bank Group entity will be the counterparty to any trading entered into by you. does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of ourtrading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws. Please read our disclaimers:
- Notification on Non-Independent Invetment Research
- Full disclaimer

Check your inbox for a mail from us to fully activate your profile. No mail? Have us re-send your verification mail